PMID- 36028823
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220906
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Aug 26
TI  - Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled 
      reanalysis based on clinical trials.
PG  - 923
LID - 10.1186/s12885-022-10015-6 [doi]
LID - 923
AB  - PURPOSE: This study aimed to explore the efficiency and safety of the new 
      generation antibody-drug conjugate Trastuzumab deruxtecan (DS-8201a) in treating 
      HER2-positive solid cancers. METHOD: By searching PubMed, Medline and Ovid for 
      all clinical trials related to the safety and efficacy of DS-8201a. Event rates 
      were calculated for all adverse events (AEs) to evaluate the safety of DS-8201a. 
      Objective response rate (ORR) and progression-free survival (PFS) were summarized 
      to assess the potency of DS-8201a. RESULT: The AEs with event rates greater than 
      30% regardless of grades were nausea, decreased appetite, vomiting, fatigue, 
      anemia, decreased neutrophil count, alopecia and diarrhea. In the grade 3 or 
      more, decreased neutrophil count, anemia and decreased white blood cell count 
      were the only three AEs with event rates greater than 10% (20.3, 15.0 and 10.3%). 
      The median PFS of patients with breast cancer, gastric cancer and other 
      HER2-positive solid cancers were 9.0-22.1, 3.0-8.3 and 4.1-11.9 months. The 
      median ORR was 37-79.9% in patients with breast and gastric cancer and 28.3-55% 
      in patients with other HER2-positive cancers. CONCLUSION: DS-8201a plays an 
      active role in treating HER2-positive cancers, especially breast and gastric 
      cancer, which have HER2 amplification. The most common AEs of DS-8201a were 
      related to gastrointestinal and hematological system. Decreased white blood cell 
      count and appetite were the AEs occurred with high grades.
CI  - (c) 2022. The Author(s).
FAU - Xu, Hanyue
AU  - Xu H
AD  - Department of Biotherapy, West China Hospital and State Key Laboratory of 
      Biotherapy, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.
AD  - Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, 
      610041, Sichuan, P.R. China.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Pancreatic Surgery, West China Hospital, Sichuan University, 
      Chengdu, 610041, Sichuan, P.R. China.
FAU - Guo, Wen
AU  - Guo W
AD  - The Center of Gerontology and Geriatrics, West China Hospital, Sichuan 
      University, Chengdu, 610041, PR China.
FAU - Zhong, Xi
AU  - Zhong X
AD  - Department of Intensive Care Unit, West China HospitalSichuan University, 
      Chengdu, 610041, PR China.
FAU - Sun, Jing
AU  - Sun J
AD  - Integrated Traditional and Western Medicine Department, Qingdao Central Hospital, 
      Qingdao University, Qingdao, Shandong, 266042, P.R. China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Biotherapy, West China Hospital and State Key Laboratory of 
      Biotherapy, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.
FAU - Wang, Zhoufeng
AU  - Wang Z
AD  - Institute of Respiratory Health, Frontiers Science Center for Disease-Related 
      Molecular Networks, West China Hospital, Sichuan University, Chengdu, 610041, 
      Sichuan, P.R. China. wangzhoufeng@wchscu.cn.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy, West China Hospital and State Key Laboratory of 
      Biotherapy, Sichuan University, Chengdu, 610041, Sichuan, P.R. China. 
      drmaxuelei@gmail.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20220826
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunoconjugates)
RN  - 5384HK7574 (trastuzumab deruxtecan)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Breast Neoplasms
MH  - Camptothecin/analogs & derivatives
MH  - Female
MH  - Humans
MH  - *Immunoconjugates
MH  - Receptor, ErbB-2
MH  - *Stomach Neoplasms
MH  - Trastuzumab
PMC - PMC9414434
OTO - NOTNLM
OT  - Adverse events
OT  - Breast cancer
OT  - Gastric cancer
OT  - Human epidermal growth factor receptor 2
OT  - Progression free survival
OT  - Trastuzumab deruxtecan (DS-8201a)
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/31 06:00
PMCR- 2022/08/26
CRDT- 2022/08/26 23:40
PHST- 2022/06/09 00:00 [received]
PHST- 2022/08/10 00:00 [accepted]
PHST- 2022/08/26 23:40 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/08/26 00:00 [pmc-release]
AID - 10.1186/s12885-022-10015-6 [pii]
AID - 10015 [pii]
AID - 10.1186/s12885-022-10015-6 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Aug 26;22(1):923. doi: 10.1186/s12885-022-10015-6.